These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37161845)

  • 21. [Efficacy and safety of IAC regimen for relapse/refractory acute myeloid leukemia: a prospective randomized controlled study].
    Li CH; Wei SN; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):287-292. PubMed ID: 35680626
    [No Abstract]   [Full Text] [Related]  

  • 22. Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial.
    Liu Y; Li Y; Zhang R; Yu Z; Jing Y
    Front Immunol; 2023; 14():1269163. PubMed ID: 38054008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML.
    Muluneh B; Buhlinger K; Deal AM; Zeidner JF; Foster MC; Jamieson KJ; Bates J; Van Deventer HW
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e13-e18. PubMed ID: 29100976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience.
    Penel-Page M; Plesa A; Girard S; Marceau-Renaut A; Renard C; Bertrand Y
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28305. PubMed ID: 32307866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens.
    Luo W; Yu H; Zou X; Ni X; Wei J
    Cancer Biomark; 2018; 23(4):485-494. PubMed ID: 30347595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
    Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients.
    Seiter K; Ahmed N; Shaikh A; Baskind P; Liu D
    Leuk Res; 2016 Jul; 46():74-8. PubMed ID: 27151544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
    Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
    Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.
    Mirza AS; Lancet JE; Sweet K; Padron E; Pinilla-Ibarz J; Nardelli L; Cubitt C; List AF; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):902-907. PubMed ID: 29030092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy and safety of Venetoclax in the treatment of 25 patients with recurrent hematologic malignancies after an allogeneic hematopoietic stem cell transplantation].
    Chen X; Liu ZY; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):542-549. PubMed ID: 36709130
    [No Abstract]   [Full Text] [Related]  

  • 31. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
    Tenold ME; Moskoff BN; Krishnan R; Rosenberg AS; Hoeg RT; Abedi M; Tuscano JM; Jonas BA
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e611-e618. PubMed ID: 33811007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MRD abnormal expression predict poor outcomes for refractory or relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Hao Q; Liu X; Zhang Y; Zhang D; Li B; Wang J
    J Clin Lab Anal; 2021 Oct; 35(10):e23974. PubMed ID: 34432318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
    Price SL; Lancet JE; George TJ; Wetzstein GA; List AF; Ho VQ; Fernandez HF; Pinilla-Ibarz J; Kharfan-Dabaja MA; Komrokji RS
    Leuk Res; 2011 Mar; 35(3):301-4. PubMed ID: 21109304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
    DiNardo CD; Lachowiez CA; Takahashi K; Loghavi S; Xiao L; Kadia T; Daver N; Adeoti M; Short NJ; Sasaki K; Wang S; Borthakur G; Issa G; Maiti A; Alvarado Y; Pemmaraju N; Montalban Bravo G; Masarova L; Yilmaz M; Jain N; Andreeff M; Jabbour E; Garcia-Manero G; Kornblau S; Ravandi F; Konopleva MY; Kantarjian HM
    J Clin Oncol; 2021 Sep; 39(25):2768-2778. PubMed ID: 34043428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
    Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
    Halpern AB; Rodríguez-Arbolí E; Othus M; Garcia KA; Percival MM; Cassaday RD; Oehler VG; Becker PS; Appelbaum JS; Abkowitz JL; Orozco JJ; Keel SB; Hendrie PC; Scott BL; Ghiuzeli MC; Estey EH; Walter RB
    Blood Adv; 2023 Sep; 7(17):4950-4961. PubMed ID: 37339483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML).
    Schnetzke U; Fix P; Spies-Weisshart B; Schrenk K; Glaser A; Fricke HJ; La Rosée P; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2014 Aug; 140(8):1391-7. PubMed ID: 24728467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of relapsed/refractory acute myeloid leukemia.
    Sun Y; Zhang J; Long B; Zhang X; Wen R; He Y; Li X
    Neoplasma; 2021 Nov; 68(6):1351-1358. PubMed ID: 34641697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.
    Ye P; Pei R; Jin J; Sun J; Li K; Cao J; Zhou D; Lu Y
    Ann Hematol; 2019 Sep; 98(9):2073-2080. PubMed ID: 31201514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.